DNTH

Dianthus Therapeutics, Inc. · NASDAQ

Sector Health Technology
Industry Biotechnology
Website dianthustx.com
Employees(FY) 32
ISIN US2528281080

Performance

+1.28%

+6.87%

-15.3%

-4.34%

+128.85%

YTD

+213.16%

Profile

Dianthus Therapeutics, Inc. operates as a clinical-stage biotechnology company that designs, develops, and delivers novel monoclonal antibodies for people living with severe autoimmune and inflammatory diseases. It develops DNTH103 that is in phase 1 clinical trails in patients with generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was incorporated in 2015 and is based in New York, New York.

Advanced Technical Analysis

Technical Analysis of DNTH 2024-12-20

The stock indicators reflect a predominantly bearish sentiment, with the Moving Average Score at 13 indicating strong downward pressure, while the Oscillators Score of 56 suggests a neutral stance. Overall, the Technical Score of 35 reinforces the bearish outlook, signaling caution for potential investors.

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of DNTH

Stock Rank

Recent News & Updates

2024-11-10 08:05
Dianthus Therapeutics Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags(Simply Wall St.)
2024-11-07 16:01
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q3 Financial Results(GlobeNewswire)
2024-11-07 03:01
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q3 Financial Results(Globenewswire)
2024-11-04 07:00
Dianthus Therapeutics to Participate in Three Upcoming Healthcare Investor Conferences(GlobeNewswire)
2024-11-03 18:00
Dianthus Therapeutics to Participate in Three Upcoming Healthcare Investor Conferences(Globenewswire)
2024-10-15 07:00
Dianthus Therapeutics Announces Two Poster Presentations for DNTH103 at the 2024 American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) Annual Meeting(GlobeNewswire)
2024-10-14 19:00
Dianthus Therapeutics Announces Two Poster Presentations for DNTH103 at the 2024 American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) Annual Meeting(Globenewswire)
2024-09-04 07:00
Dianthus Therapeutics to Participate in Three Healthcare Investor Conferences in September(GlobeNewswire)
2024-09-03 19:00
Dianthus Therapeutics to Participate in Three Healthcare Investor Conferences in September(Globenewswire)
2024-08-10 08:05
Dianthus Therapeutics Second Quarter 2024 Earnings: Beats Expectations(Simply Wall St.)
2024-08-08 16:01
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q2 Financial Results(GlobeNewswire)
2024-08-08 04:01
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q2 Financial Results(Globenewswire)
2024-07-07 23:06
Dianthus (DNTH) Gains 18% in the Past Month: Here's Why(Zacks)
2024-06-28 11:30
Dianthus Therapeutics Announces Two Poster Presentations for DNTH103 at the 10th Congress of the European Academy of Neurology (EAN)(GlobeNewswire)
2024-06-27 23:30
Dianthus Therapeutics Announces Two Poster Presentations for DNTH103 at the 10th Congress of the European Academy of Neurology (EAN)(Globenewswire)
2024-06-12 07:00
Dianthus Therapeutics Announces FDA Clearance to Initiate Phase 2 Trial of DNTH103 in Multifocal Motor Neuropathy (MMN)(GlobeNewswire)
2024-06-11 19:00
Dianthus Therapeutics Announces FDA Clearance to Initiate Phase 2 Trial of DNTH103 in Multifocal Motor Neuropathy (MMN)(Globenewswire)
2024-05-30 16:30
Dianthus Therapeutics to Participate in the Jefferies Global Healthcare Conference(GlobeNewswire)
2024-05-30 04:30
Dianthus Therapeutics to Participate in the Jefferies Global Healthcare Conference(Globenewswire)
2024-05-21 08:01
Companies Like Dianthus Therapeutics (NASDAQ:DNTH) Are In A Position To Invest In Growth(Simply Wall St.)
2024-05-09 16:01
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 Financial Results(GlobeNewswire)
2024-05-09 10:56
DNTH Stock Earnings: Dianthus Therapeutics Misses EPS, Beats Revenue for Q1 2024(Investorplace)
2024-05-09 04:01
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 Financial Results(Globenewswire)
2024-05-08 16:30
Dianthus Therapeutics to Participate in the Bank of America Securities 2024 Health Care Conference(GlobeNewswire)
2024-05-08 04:30
Dianthus Therapeutics to Participate in the Bank of America Securities 2024 Health Care Conference(Globenewswire)
2024-05-03 16:30
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)(GlobeNewswire)
2024-05-03 04:30
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)(Globenewswire)
2024-04-11 07:30
Dianthus Therapeutics Announces Oral Presentation for DNTH103 at the 2024 American Academy of Neurology (AAN) Annual Meeting(GlobeNewswire)
2024-04-10 19:30
Dianthus Therapeutics Announces Oral Presentation for DNTH103 at the 2024 American Academy of Neurology (AAN) Annual Meeting(Globenewswire)
2024-04-05 16:30
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)(GlobeNewswire)

Page 1 of 5

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.